Mesoblast (ASX:MSB) secured a regenerative advanced therapy designation from the US Food and Drug Administration for Revascor-branded rexlemestrocel-L cell therapy for pediatric patients with congenital heart disease, according to a Thursday filing with the Australian bourse.
The status was granted following results from a clinical trial investigating the use of the therapy in children with hypoplastic left heart syndrome (HLHS), the filing said.
Revascor was previously granted by the health regulator with both a rare pediatric disease designation and an orphan drug designation for pediatric patients with HLHS, the filing added.
The company's shares tumbled almost 8% in recent Thursday trade but earlier hit their highest since August 2021.
Price (AUD): $1.62, Change: $-0.14, Percent Change: -7.95%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。